TARDBP Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q13148 |
---|---|
Clone Names | 100427274 |
Gene ID | 23435 |
---|---|
Other Names | TAR DNA-binding protein 43, TDP-43, TARDBP, TDP43 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13763a was selected from the N-term region of TARDBP. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | TARDBP {ECO:0000303|PubMed:18396105, ECO:0000312|HGNC:HGNC:11571} |
---|---|
Function | RNA-binding protein that is involved in various steps of RNA biogenesis and processing (PubMed:23519609). Preferentially binds, via its two RNA recognition motifs RRM1 and RRM2, to GU-repeats on RNA molecules predominantly localized within long introns and in the 3'UTR of mRNAs (PubMed:23519609, PubMed:24240615, PubMed:24464995). In turn, regulates the splicing of many non-coding and protein-coding RNAs including proteins involved in neuronal survival, as well as mRNAs that encode proteins relevant for neurodegenerative diseases (PubMed:21358640, PubMed:29438978). Plays a role in maintaining mitochondrial homeostasis by regulating the processing of mitochondrial transcripts (PubMed:28794432). Regulates also mRNA stability by recruiting CNOT7/CAF1 deadenylase on mRNA 3'UTR leading to poly(A) tail deadenylation and thus shortening (PubMed:30520513). In response to oxidative insult, associates with stalled ribosomes localized to stress granules (SGs) and contributes to cell survival (PubMed:23398327, PubMed:19765185). Participates also in the normal skeletal muscle formation and regeneration, forming cytoplasmic myo-granules and binding mRNAs that encode sarcomeric proteins (PubMed:30464263). Plays a role in the maintenance of the circadian clock periodicity via stabilization of the CRY1 and CRY2 proteins in a FBXL3-dependent manner (PubMed:27123980). Negatively regulates the expression of CDK6 (PubMed:19760257). Regulates the expression of HDAC6, ATG7 and VCP in a PPIA/CYPA-dependent manner (PubMed:25678563). |
Cellular Location | Nucleus. Cytoplasm. Cytoplasm, Stress granule Mitochondrion. Note=Continuously travels in and out of the nucleus (PubMed:18957508). Localizes to stress granules in response to oxidative stress (PubMed:19765185). A small subset localizes in mitochondria (PubMed:28794432). |
Tissue Location | Ubiquitously expressed. In particular, expression is high in pancreas, placenta, lung, genital tract and spleen |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
HIV-1, the causative agent of acquired immunodeficiencysyndrome (AIDS), contains an RNA genome that produces achromosomally integrated DNA during the replicative cycle.Activation of HIV-1 gene expression by the transactivator Tat isdependent on an RNA regulatory element (TAR) located downstream ofthe transcription initiation site. The protein encoded by this geneis a transcriptional repressor that binds to chromosomallyintegrated TAR DNA and represses HIV-1 transcription. In addition,this protein regulates alternate splicing of the CFTR gene. Asimilar pseudogene is present on chromosome 20. [provided byRefSeq].
References
Kim, S.H., et al. J. Biol. Chem. 285(44):34097-34105(2010)Geser, F., et al. Arch. Neurol. 67(10):1238-1250(2010)Mackenzie, I.R., et al. Lancet Neurol 9(10):995-1007(2010)Shan, X., et al. Proc. Natl. Acad. Sci. U.S.A. 107(37):16325-16330(2010)McKee, A.C., et al. J. Neuropathol. Exp. Neurol. 69(9):918-929(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.